[Post-marketing observational study of donepezil].
Ibach
Bernd
B
D000368:Aged; D000544:Alzheimer Disease / Q000451:nursing*; D002800:Cholinesterase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D000077265:Donepezil; D004359:Drug Therapy, Combination; D006801:Humans; D007189:Indans / Q000009:adverse effects / Q000627:therapeutic use*; D018697:Nootropic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use*; D011358:Product Surveillance, Postmarketing; D019233:Retreatment; D016896:Treatment Outcome
D002800:Cholinesterase Inhibitors; D007189:Indans; D018697:Nootropic Agents; D010880:Piperidines; D000077265:Donepezil